Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 65 of 620 for:    oximeter

Validation of Fore-Sight Cerebral & Tissue Oximeter Saturation Measurements on Neonates ≤ 5 kg (FORE-SIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02017652
Recruitment Status : Completed
First Posted : December 23, 2013
Last Update Posted : October 9, 2017
Sponsor:
Information provided by (Responsible Party):
Anup Katheria, M.D., Sharp HealthCare

Brief Summary:
CASMED, INC. wishes to validate the next generation FORE-SIGHT-II (FS-II) NIRS tissue oximeter monitor for neonatal brain and somatic tissue oxygen saturation (StO2) measurements. This monitor was recently FDA cleared for use on adult subjects.

Condition or disease
Bowel Motility

Detailed Description:
  1. Validate FS-II abdominal StO2 measurements from the intestines, liver, and flank to umbilical venous and arterial blood oxygen saturation.
  2. Validate FS-II cerebral StO2 measurements against the predicate FDA cleared FORE-SIGHT-I (FS-I) monitor.
  3. Collect data from FS-II sensors on the forehead and abdomen (intestine) for 24 hours to compare dynamic changes vs the pulse oximeter. For larger neonates, add a predicate FS-I sensor to the opposite side forehead for dynamic comparison to FS-II measurements.
  4. Obtain abdominal Near Infrared Spectroscopy (NIRS) data simultaneous with accepted measures of bowel motility (a. frequency and composition of stools, and b. Ultrasound assessment for the frequency and magnitude of bowel peristalsis, if available).

Layout table for study information
Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of FORE-SIGHT Cerebral & Tissue Oximeter to Measure Cerebral & Somatic Tissue Oxygen Saturation Measurements at Different Body Locations on Neonates ≤ 5 kg
Study Start Date : December 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Group/Cohort
Preterm Infants
Preterm infants 32 to 36 weeks will be eligible for this study



Primary Outcome Measures :
  1. StO2 measurement from intestines, liver and flank at time of venous and arterial blood oxygen saturation. [ Time Frame: 1 hour ]
    At or immediately following an umbilical venous blood draw for CO-oximetry, the FS-II NIRS Small sensor will be briefly placed on the abdominal wall for spot check measurements over the 1) left & 2) right flank, 3) liver and on three intestine locations: just inferior and lateral to the umbilicus in the 4) Right Lower Quadrant (RLQ) and 5) Left Lower Quadrant (LLQ) positions, as well as 6) Mid Lower Quadrant (MLQ). Then a reference FS-I measurement of the 7) flank for 2 minutes will be done.

  2. Cerebral StO2 measurements from Fore-Sight FS-II monitor and Fore-Sight-I (FS-I) monitor. [ Time Frame: 1 hour ]
    Following abdominal measurements, the FS-II Small sensor will be placed on the head with the following positions in the following sequence 1) forehead, over the frontal cortex for two minutes; 2) the FS-II sensor is lifted off the head and placed back in the same forehead position to make a repeat measurement for two minutes; and 3) on the side of the head above the ear (frontal and parietal cortex) for two minutes. For reference cerebral measurements, a FDA cleared FS-I Small sensor will be placed on the 4) forehead for two minutes; 5) the FS-I sensor will be removed and replaced on the same forehead position to make a repeat measurement for two minutes. The sensors will take a measurement of 2 minutes in each position and 10 minutes total.

  3. Pulse and Tissue oxygen saturation and infant activity [ Time Frame: 24 hours ]
    Then two FS-II Small sensors will be attached longer term, one sensor on the forehead and one sensor on the abdomen (RLQ), with neonatal adhesives to allow monitoring for up to 24 hours. Dynamic changes of StO2 at these locations will be observed, along with pulse oximetry SpO2 to capture any acute events such as apnea and bradycardia, which will help in modeling and verifying dynamic StO2 change behavior within the FS-II algorithm. FS-II, and pulse oximetry data will be collected simultaneously on a laptop computer.

  4. Stool Interference Index over 24 hrs. [ Time Frame: 24 hours ]
    To calculate abdominal StO2 over the intestine regions, FORE-SIGHT also measures a stool interference index, which is used to compensate the algorithm to calculate StO2 correctly. This stool interference index is hypothesized to be also useful as a bowel motility index based on its variability over time. To test this hypothesis, the following two references for bowel motility will be tested: a) the study site will minimally record the number of stools for a period up to 24 hours. The event field in the laptop computer will be used to note each observation. b) if the study site has the capacity, abdominal ultrasound will be used to observe for the frequency and magnitude of bowel peristalsis. These impressions will be added to an event field in the laptop computer.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 7 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Neonatal subjects (32 to 36 and 6/7 weeks), with umbilical venous catheterization will be enrolled from the NICU. Demographic information of the subject will be recorded, including race, gender, weight, gestational age (GA), study age, and diagnosis.
Criteria

Inclusion Criteria:

Neonatal subjects (32 to 36 and 6/7 weeks), with umbilical venous catheterization will be enrolled from the Neonatal Intensive Care Unit.

Exclusion Criteria:

Enrollment in other studies during study period. Inability to tolerate ultrasounds or NIRS sensors


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02017652


Locations
Layout table for location information
United States, California
Sharp Mary Birch Hospital for Women and Newborns
San Diego, California, United States, 92123
Sponsors and Collaborators
Sharp HealthCare
Investigators
Layout table for investigator information
Principal Investigator: Anuup Katheria, MD Sharp Mary Birch Hospital for Women & Newborns

Layout table for additonal information
Responsible Party: Anup Katheria, M.D., Director of Neonatal Research, Sharp HealthCare
ClinicalTrials.gov Identifier: NCT02017652     History of Changes
Other Study ID Numbers: FORE-SIGHT
First Posted: December 23, 2013    Key Record Dates
Last Update Posted: October 9, 2017
Last Verified: October 2017
Keywords provided by Anup Katheria, M.D., Sharp HealthCare:
bowel motility
cerebral perfusion
intestinal perfusion